What this covers
This is a conversation between Matt and Jim that works through Doximity as a business. It begins with the company's origins. CEO Jeff earlier founded Hippocrates, a mobile drug reference tool later sold to athenahealth, and co-founded Doximity in 2010 with Nate Gross and Shari Buck. It went public in 2021. Jim then traces how a LinkedIn-style network became a daily toolkit: a newsfeed that pays out CME credits, digital signing, HIPAA-compliant faxing and messaging, telehealth calling that shows the hospital's caller ID, and AI tools. The newsfeed is filtered by machine learning, branded "cutting the scut," and carries roughly one ad per 11 items.
The second half turns to the advertising side. Jim frames the platform as a Bloomberg terminal to doctors and a Facebook to advertisers, since physicians self-declare their identity and location. He explains why digital pharma ads can be measured when TV cannot, and cites several forces: "no-see" physicians who refuse rep visits, COVID closing hospitals to reps, and digital-first biotechs. He puts digital penetration in healthcare at about half the roughly 75% seen elsewhere. A contested point is a federal order adding about 30 seconds of risk disclosure to DTC TV ads, which he argues pushes spend elsewhere.
The closing themes are valuation and risk. Jim argues for starting from cash flows, growth and moat rather than comparables, and he disputes sell-side price-to-sales multiples. He says the market treats Doximity too much as ad tech and doubts its strong quarters. The main risk he names is anything that gives doctors a reason to leave, including competitors who capture their attention.
Doximity's moat is a doctor-centric workflow platform that is good enough to keep physicians engaged, and because pharma ad budgets follow engagement and measurable ROI, the company has a long runway of digital ad share gains with very high incremental margins.
- Consolidating point solutions onto one platform keeps physicians on it, which makes their attention the monetizable asset
- Pharma's shift from TV, print, and reps to digital is driven by measurable ROI and runs well behind the rest of the economy
- Ad revenue carries about 90% gross margins and 55% EBITDA margins, so growth converts to earnings quickly
Doximity's professional audience is valuable to advertisers, as Meta and Google's ROI and attention models show.
- Matt argues that Meta and Google built large businesses on the thesis that measurable ROI and eyeball attention are what advertisers pay for, which supports Doximity's case.
“They built quite impressive businesses on the back of that thesis alone, the ability to measure the ROI in your ad spend, so certainly checks out.”
- Matt argues that B2B media is the most attractive business model, and Doximity is a strong example because its audience of professionals is valuable to advertisers.
“I always looked at B2B media as the most attractive model, and Doximity's story is the perfect example of why.”
Doximity's dominant physician network reflects medicine's distinct position as an AI-impacted sector.
- As of November 2025, agentic AI is expected to be more of a benefit to existing corporations than a threat, though medicine is a notable exception where AI could have the largest impact.
“I would expect that most of agentic AI is just a benefit to existing corporations more than a threat”
- Doximity has roughly 80% penetration among doctors, which makes the 'LinkedIn for doctors' description fair and gives the company a dominant position in the physician network.
“with 80% of doctors on their platform, I think that's a fair categorization.”